Van Veldhoven Afdeling Farmacologie, Department of Molecular Cell Biology, Katholieke Universiteit Leuven, Belgium 3-Methyl-branched fatty acids, as phytanic acid, undergo peroxisomal a-
Trang 1R E V I E W A R T I C L E
Alpha-oxidation of 3-methyl-substituted fatty acids
and its thiamine dependence
Minne Casteels, Veerle Foulon, Guy P Mannaerts and Paul P Van Veldhoven
Afdeling Farmacologie, Department of Molecular Cell Biology, Katholieke Universiteit Leuven, Belgium
3-Methyl-branched fatty acids, as phytanic acid, undergo
peroxisomal a-oxidation in which they are shortened by 1
carbon atom This process includes four steps: activation,
2-hydroxylation, thiamine pyrophosphate dependent
cleavage and aldehyde dehydrogenation The thiamine
pyrophosphate dependence of the third step is unique in
peroxisomal mammalian enzymology Human pathology
due to a deficient alpha-oxidation is mostly linked to mutations in the gene coding for the second enzyme of the sequence, phytanoyl-CoA hydroxylase
Keywords: alpha-oxidation; thiamine pyrophosphate; per-oxisomes; lyase; Adult Refsum Disease
Introduction
a-Oxidation is the process in which fatty acids are shortened
at the carboxyl-end by one carbon atom For
3-methyl-branched fatty acids, this is the preferred pathway as their
breakdown by b-oxidation is impossible Indeed, the
3-methyl-branch precludes the third step of b-oxidation,
the dehydrogenation step Phytanic acid
(3,7,11,15-tetra-methylhexadecanoic acid) is at present the only established
physiological substrate of a-oxidation in humans [1,2]
Phytanic acid is derived from phytol, the isoprenoid side
chain of chlorophyll As chlorophyll-bound phytol cannot
be metabolized by humans, and free phytol is present only
in minimal quantities in food, the phytanic acid present in
the human body is mostly provided by external sources
(Fig 1) Ruminants ingest large amounts of chlorophyll,
from which phytol is efficiently cleaved off by bacteria in the
gastrointestinal tract Phytol is subsequently taken up and
converted to phytanic acid, which is deposited in fat tissues
and in milk, the major sources of phytanic acid for humans
[2]
Accumulation of phytanic acid is typically seen in Adult
Refsum Disease (ARD) and is due to a deficient
degrada-tion of this exogenous 3-methyl-branched fatty acid [2,3]
Elevated phytanic acid levels can also be seen in peroxisome
biogenesis disorders, in which a defective a-oxidation is only
one of the deficiencies present [4] Degradation of phytanic
acid via x-oxidation, by which a carboxylic acid group is
introduced at the omega end, has also been described [5,6], but appears to be quantitatively less important under physiological conditions Its importance increases when phytanic acid levels in serum are elevated as is seen in ARD [7]
The degradation of phytanic acid via a-oxidation is presently proposed to evolve completely in peroxisomes, some doubts remaining, however, concerning the first (activation) and last (aldehyde dehydrogenation) enzymatic steps
Degradation of 3-methyl-branched fatty acids The classic catabolic pathway by which fatty acids are degraded is b-oxidation and a mitochondrial as well as a peroxisomal b-oxidation pathway is known [8] Very long chain fatty acids, 2-methyl-branched fatty acids, the side chains of bile acid intermediates and eicosanoids are mainly/ exclusively handled by the peroxisomal pathway, whereas short and medium chain fatty acids are oxidized mainly in mitochondria [8]
Phytanic acid and other 3-methyl-branched fatty acids cannot undergo b-oxidation because the 3-methyl-group prevents the formation of a 3-keto substituent in the dehydrogenation step Therefore, 3-methyl-branched fatty acids first undergo a-oxidation In the case of phytanic acid, this results in the generation of 2-methyl-branched pristanic acid (2,6,10,14-tetramethylpentadecanoic acid), which is then shortened to 4,8-dimethylnonanoic acid via peroxi-somal b-oxidation The dimethyl fatty acid is then degraded further via mitochondrial b-oxidation
Peroxisomes, in which most or all steps of the a-oxidation pathway evolve, are subcellular organelles involved in a number of anabolic (e.g plasmalogen synthesis) and catabolic processes, including a- and b-oxidation [8] Peroxisomal enzymes are synthesized on polyribosomes in the cytosol and are post-translationally imported into the peroxisome Therefore, these enzymes contain a series of conserved amino acids or so called peroxisome targeting signals (PTSs) [9] Two classes of these topogenic sequences
Correspondence to M Casteels, Afdeling Farmacologie, Department
of Molecular Cell Biology, Katholieke Universiteit Leuven,
Campus Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium.
Fax: + 32 16 345699, Tel.: + 32 16 345816,
E-mail: minne.casteels@med.kuleuven.ac.be
Abbreviations: PAHX, phytanoyl-CoA hydroxylase; 2-HPCL,
2-hydroxyphytanoyl-CoA lyase; ARD, Adult Refsum Disease;
PTS, peroxisome targeting signal; TPP, thiamine pyrophosphate.
(Received 15 November 2002, revised 15 February 2003,
accepted 21 February 2003)
Trang 2have been described: PTS1, a carboxy-terminal tripeptide,
and PTS2, an amino-terminal nonapeptide [9] A defect in
the PTS-receptors or other components of the import
machinery results in a generalized peroxisome biogenesis
disorder [4]
a-Oxidation of 3-methyl-branched fatty acids has already
been studied in the sixties and seventies, but only in the last
decade have most aspects of a-oxidation been unravelled [8]
For the study of this pathway both the natural substrate
phytanic acid, racemic at carbon 3, and the synthetic
(3-R,S)-methylhexadecanoic and
(3-R,S)-methylheptadeca-noic acids, have been used It has been shown that the
synthetic 3-methyl-branched fatty acids are metabolized in
the same way as phytanic acid [10], and can validly be used
as substitutes for the latter substrate when studying
a-oxidation A major breakthrough in a-oxidation research
was Poulos’ finding that in fibroblasts a-oxidation of
3-methyl-branched fatty acids generates not only CO2, as
was generally believed, but also formate [11] Up till then
only CO2had been measured as an end product, and major
discrepancies existed between oxidation rates obtained in
intact cells (isolated hepatocytes, confluent fibroblasts),
permeabilized hepatocytes and broken cell systems (liver
homogenates, subcellular fractions) [8] Subsequent
meas-urements of formate (plus formyl-CoA, see below) and CO2
resolved the discrepancies between intact and
permeabi-lized/broken systems and allowed for the dissection of the
a-oxidation process Our present knowledge of the
enzy-matic sequence is shown in Fig 2
In a first step the 3-methyl-branched fatty acid is activated
to the corresponding CoA-ester by an acyl-CoA synthetase
which is most probably present in the peroxisomal
membrane It is not yet clear which synthetase is responsible for the activation step: a nonspecific long chain fatty acyl-CoA synthetase [12], a specific phytanoyl-acyl-CoA synthetase [13] or a very long chain fatty acyl-CoA synthetase [14] The second step is responsible for the iron dependence of the pathway [15], which had been described by several authors in the past but was regarded as doubtful concerning its physiological relevance [16,17] In this step the 3-methylacyl-CoA is hydroxylated in position 2 by a dioxygenase, which is dependent on molecular O2, iron, 2-oxoglutarate, ascorbate, ATP/GTP and Mg2+ [18–21] This dioxygenase, named phytanoyl-CoA hydroxylase (PAHX), contains a PTS2-signal and is present in the peroxisomal matrix [22,23] The product of the reaction
Fig 1 Chemical structures of chlorophyll, phytol and phytanic acid
(3,7,11,15-tetramethylhexadecanoic acid).
Fig 2 a-Oxidation of 3-methyl-branched fatty acids The scheme represents the a-oxidation pathway of phytanic acid The numbers indicate the enzymes catalysing the different steps: (1) acyl-CoA syn-thetase; (2) phytanoyl-CoA hydroxylase (PAHX); (3) 2-hydroxy-phytanoyl-CoA lyase (2-HPCL); (4) aldehyde dehydrogenase; and (5) formyl-CoA hydrolase.
Trang 3catalysed by PAHX is a 2-hydroxy-3-methylacyl-CoA, or, if
phytanic acid is the substrate, 2-hydroxyphytanoyl-CoA
The PAHX gene is located on chromosome 10 [22], and
mutations of this gene are probably the most frequent cause
of ARD [22–25] Structure-function analysis of PAHX
further revealed that at least four different types of
mutations can cause loss of enzyme activity [25]
In the third step, 2-hydroxy-3-methylacyl-CoA is cleaved
in the peroxisomal matrix [26,27] by
2-hydroxyphytanoyl-CoA lyase (2-HPCL), which uses thiamine pyrophosphate
(TPP) as cofactor [26] Products of this reaction are
formyl-CoA [28] and a 2-methyl-branched fatty aldehyde (pristanal
when 2-hydroxyphytanoyl-CoA is cleaved) [29,30], both of
which had been identified before the discovery of the lyase
(see below)
The 2-methyl-branched fatty aldehyde is subsequently
dehydrogenated by an NAD+-dependent aldehyde
dehy-drogenase to a 2-methyl-branched fatty acid (pristanic acid
in the case of pristanal), which can be activated to the
corresponding acyl-CoA ester This CoA-ester can then
enter the peroxisomal b-oxidation sequence The 2-methyl
aldehyde dehydrogenase activity is located in the
peroxi-somal matrixaccording to Croes et al [29] and in the
endoplasmic reticulum (microsomes) according to
Verho-even et al [30] It remains at present unclear which aldehyde
dehydrogenase is involved Measurements in Sjo¨gren–
Larsson syndrome (SLS) fibroblasts, the microsomal
alde-hyde dehydrogenase of which is deficient, show only a 30%
decrease in dehydrogenation rates of pristanal [31,32] and
make an exclusive role of a microsomal aldehyde
dehy-drogenase unlikely
The major part of formyl-CoA is enzymatically converted
to formate in peroxisomes [28] It was shown previously [33] that in rats, aminotriazole, known as an inhibitor of catalase, had little effect on the conversion of14C-formate to
CO2(but decreased the rates of a-oxidation by 90%) In rat formate is metabolized by two pathways: the catalase pathway and the tetrahydrofolate pathway, important in one carbon-metabolism [34] The data on aminotriazole indicate that at least in the rat the catalase pathway is of no paramount importance, and suggest that the tetrahydro-folate pathway is quantitatively more important for formate metabolism [33] We studied the conversion of14C-formate
to14CO2in rat and found it to be localized mainly in the cytosolic fraction, and to be stimulated by NAD+[19] No further work on the fate of formate as a product of a-oxidation has been published since Nothing is known
on the export of formate from the peroxisome, but it is supposed that formate, as well as other small organic acids can leak from the peroxisomes [35]
Table 1 gives an overview of the presently known characteristics of the four main enzymes of the a-oxidation pathway
Stereospecificity of the a-oxidation pathway Phytol has two chiral centres, one at carbon 7 and one at carbon 11, both of which are of the R-configuration [41] Non-specific reduction of the double bond in phytol leads
to the production of two diastereoisomers: (3S,7R,11R)-and (3R,7R,11R)-phytanic acid [42] Phytanic acid from all common sources is a mixture of these two
Table 1 Properties of the enzymatic steps/enzymes of the a-oxidation pathway The table gives an overview of the present knowledge of some of the properties of the enzymes involved in the initial degradation of 3-methyl-branched fatty acids in humans See text for details.
Acyl-CoA synthetase
Phytanoyl-CoA hydroxylase (PAHX)
2-Hydroxyphytanoyl-CoA lyase (2-HPCL)
Aldehyde dehydrogenase
Gene mapping 10p15.1 [22] 3p25 [39]
Mass of subunit Unprocessed: 38 556/
mature: 35 436 Da
Monomer: 63 732 Da Cofactors ATP, CoA, Mg2+ O2, Fe2+, ascorbate, 2-oxoglutarate
[18,19]
TPP, Mg2+[26] NAD+[29,30] ATP/GTP, Mg 2+ [21]
K m for CoA-ester 29.5 ± 1.7 lMb[36] 15 lMd[26]
Subcellular localization Peroxisomal
membrane [12–14]?
Peroxisomal matrix [19,20] Peroxisomal matrix [26,27] Peroxisomes
[29,32]? Targeting PTS-2 [22,23] PTS-1 [26]
Stereochemistry Not stereospecifica 3Rfi2S,3R; 3Sfi2R,3S c
[37,38] Not stereospecific [38] Unknowne Heterologous expression
systems
E coli Mammalian cells,
S cerevisiae [26,39]
Mutagenesis studies Yes [22,24,25] No
Structural information Yes [25] TPP binding domain [26,39]
a
As both phytanic acid and phytanoyl-CoA are racemic at position 3, it is supposed that the acyl-CoA synthetase is not stereospecific Whether the activation rates for the R- and S-isomers are different, as shown for the conversion of 2-methyl-branched fatty acids to the corresponding acyl-CoA esters in human liver [40], is not known b K m determined for phytanoyl-CoA with recombinant PAHX, in the presence of equimolar concentrations of SCP-2.cPhytanoyl-CoA hydroxylase is not stereospecific, but the configuration of the methyl-branch at position 3 determines the orientation of the hydroxy-group at position 2 Eventually, only (2R,3S) and (2S,3R) isomers are formed d K m determined for 2-hydroxy-3-methyl-C16-CoA with partially purified enzyme e Although nothing is known about the stereo-specificity of aldehyde dehydrogenases, it can be postulated from all different data concerning the stereochemistry of the a-oxidation pathway that this last step of the reaction sequence is not stereospecific.
Trang 4diastereoisomers and their ratios are variable and
depend-ent on sample origin As the a-oxidation product of
racemic phytanic acid, pristanic acid, is racemic at
position 2, it seems obvious that both stereoisomers can
undergo a-oxidation without a previous isomerization at
the initial 3-methyl-branch Croes et al [38] provided
indeed evidence that isomerization of the 3-methyl-branch
during a-oxidation does not occur and that the
configur-ation of the methyl-branch is conserved throughout the
whole a-oxidation process It was also demonstrated that
the configuration of the 3-methyl-branch does not
influ-ence the rate of a-oxidation, but determines the
orienta-tion of the 2-hydroxylaorienta-tion This explains the formaorienta-tion
of only the (2S,3R) and (2R,3S) isomers of
2-hydroxy-3-methylhexadecanoyl-CoA by purified peroxisomes, despite
the experimental finding that all four possible isomers
(although each to a different extent) can be metabolized
[38] The data of Croes et al confirm the earlier findings
of Tsai [37], who concluded that the introduction of the
hydroxy group at position 2 is stereospecific and
deter-mined by the configuration of the methyl group at
position 3 The stereochemistry of the a-oxidation
path-way is presented in Fig 3
The lack of stereospecificity of the a-oxidation pathway is
in contrast with the stereospecificity of both the peroxisomal
and mitochondrial b-oxidation systems As a-oxidation of
phytanic acid results in both stereoisomers of pristanic acid,
the produced (2R,6R,10R) isomer has to undergo
racemi-zation at carbon 2 before b-oxidation can take place In
addition, racemization at the other chiral centres is an essential step for the further b-oxidation of the intermediate a-methyl fatty acids [40]
2-HPCL: a thiamine dependent enzyme 2-HPCL identification
After the discovery by Poulos et al [11] of formate as a product of a-oxidation in fibroblasts, a finding which was confirmed in isolated hepatocytes [33], Croes et al found in
1997 that not formate (or CO2) was the primary end product but formyl-CoA [28] This finding led several authors to propose a reaction mechanism in which the other product would be a 2-methyl-branched aldehyde (or pristanal in case phytanic acid is the substrate) Soon, the formation of a 2-methyl-branched aldehyde, using 2-hydroxy-3-methylacyl-CoA or 2-hydroxyphytanoyl-CoA
as precursor, was demonstrated simultaneously by Croes
et al [29] and Verhoeven et al [30]
Foulon et al used 2-hydroxy-3-methylhexadecanoyl-CoA as substrate for studying the third reaction of the a-oxidation pathway, and measured formate (together with formyl-CoA, which is, partly enzymatically, converted to formate) as the reaction product [26]
Subcellular fractionation studies in rat liver demonstra-ted that the lyase activity colocalized with catalase in the peroxisomal fraction [26] Hence, isolation of the pre-sumptive cleavage enzyme was started from the matrix protein fraction of isolated rat liver peroxisomes The purified lyase was made up of four identical subunits of
63 kDa Formyl-CoA and 2-methylpentadecanal (meas-ured by GC-analysis) were identified as reaction products when the enzyme (in the presence of thiamine pyrophos-phate (TPP), see below) was incubated with 2-hydroxy-3-methylhexadecanoyl-CoA as the substrate Quantitative measurements of both reaction products further confirmed the stoichiometry of the cleavage step Incubations in the presence of NAD+ (a cofactor for fatty aldehyde dehydrogenation [43]) did not alter the amount of formate (formyl-CoA) and 2-methyl-pentadecanal formed, and no conversion of the aldehyde to a fatty acid could be demonstrated indicating that this reaction is performed by
a separate enzyme Hence, as the only activity of the purified enzyme is the specific cleavage of a carbon-carbon bond, it was called 2-hydroxyphytanoyl-CoA lyase or 2-HPCL [26]
An apparent Km of 15 lMfor 2-hydroxy-3-methylhexa-decanoyl-CoA was calculated The pH optimum was between 7.5 and 8.0 [26]
TPP-dependence of 2-HPCL Originally, 2-HPCL had been purified in the absence of TPP and the enzyme lost virtually all of its activity during purification The amino-acid sequences of tryptic peptides from the purified and barely active 2-HPCL suggested that the cleavage enzyme is related to a putative Caenorhabditis elegansprotein that displays homology to bacterial oxalyl-CoA decarboxylases [44,45] These enzymes, which have hitherto only been described in bacteria, catalyse the TPP-dependent decarboxylation of oxalyl-CoA to formyl-CoA
Fig 3 Stereochemistry of the a-oxidation pathway The scheme
rep-resents the a-oxidation pathway of (3R,3S)-methylhexadecanoic acid
and the stereochemical configuration of the intermediates involved.
The numbers indicate the enzymes catalysing the different steps: (1)
acyl-CoA synthetase; (2) phytanoyl-CoA hydroxylase (PAHX); (3)
2-hydroxyphytanoyl-CoA lyase (2-HPCL); (4) aldehyde
dehydro-genase; (5) formyl-CoA hydrolase; (6) acyl-CoA synthetase; and (7)
2-methylacyl-CoA racemase, responsible for the conversion of the
2R-methylacyl-CoA into the 2S-methylacyl-CoA, as only the S-isomer
can undergo b-oxidation.
Trang 5and CO2 [44,45] This homology suggested that also
2-HPCL might require TPP, an unexpected cofactor for
a-oxidation
In the presence of 0.8 mM Mg2+, optimum activity for
the purified enzyme was reached at 20 lM TPP (Km for
TPP¼ 8.43 lM) Only minor stimulation by TPP was
noted in a fresh liver homogenate (1.3 fold), and a gradually
more potent stimulation of the lyase activity was observed
as the enzyme became more purified Hence, optimal lyase
measurements have to be performed in the presence of TPP
and MgCl2
cDNA and amino-acid sequence
The cDNA sequence of the human lyase contains an open
reading frame of 1734 nucleotides encoding a polypeptide
with a calculated molecular mass of 63 732 Da Similarly
to other TPP-dependent enzymes (e.g bacterial
oxalyl-CoA decarboxylases), a TPP-binding consensus domain
could be identified in the C-terminal part of the lyase The
corresponding peptide sequences of this domain in the
human, mouse and rat enzyme, comply exactly with
the TPP consensus domain of pyruvate decarboxylase of
Saccharomyces cerevisiae, acetolactate synthase of
Escheri-chia coli, oxalyl-CoA decarboxylase of Oxalobacter
formi-genes and the putative oxalyl-CoA decarboxylases of
Caenorhabditis elegans and S cerevisiae [44,45] (Fig 4
[46])
Substrate specificity of 2-HPCL
Recombinant human protein, expressed in mammalian cells
or in a yeast system, clearly exhibited lyase activity, whereas
expression in a bacterial system did not result in a
functionally active enzyme [26]
Study of the substrate specificity of recombinant
human lyase revealed that the enzyme is not only active
towards 2-hydroxy-3-methylhexadecanoyl-CoA (the
analogue of 2-hydroxyphytanoyl-CoA), but also,
although to a minor extent, towards
2-hydroxyoctadeca-noyl-CoA (± 12% of control activity) at equal substrate
concentration The latter compound, however, as well as
2-hydroxyhexadecanoyl-CoA, effected a very strong
inhi-bition on the cleavage of
2-hydroxy-3-methylhexadeca-noyl-CoA, most probably due to competition [39] No
activity at all was seen with
2-hydroxy-3-methylhexadeca-noic acid, 3-methylhexadeca2-hydroxy-3-methylhexadeca-noic acid or 3-methylhexa-decanoyl-CoA, indicating that both a 2-hydroxy group and a CoA-moiety, but not a 3-methyl-branch, are necessary for lyase activity [39]
Identification of novel PTS
At first glance, the Hs 2-HPCL sequence did not contain a C-terminal or N-terminal peroxisome targeting signal (PTS) As the C elegans orthologue ends in a putative PTS1 (SKM) and as PRL, the C-terminal tripeptide of the
S cerevisiae orthologue, had been shown to bind to the human PTS1 import receptor [47], the C-terminal sequence SNM, which is also conserved in the mouse counterpart, was considered to have a targeting function Transfection studies with constructs coding for 2-HPCL fused to GFP revealed that the fluorescence localized to peroxisomes in fibroblasts from PEX5+/– mice and to the cytosol in fibroblasts from PEX5–/–mice [26] The latter mice lack the PTS1 receptor (Pex5p) and do not import PTS1-containing proteins into their peroxisomes [48] As a GFP-construct containing only the last 5 amino acids of 2-HPCL localized
to peroxisomes in fibroblasts from normal mice, we can conclude that targeting information is present within this pentapeptide and that SNM, preceded by a positive charge,
is a hitherto unrecognized PTS1 [26]
Reaction mechanism of 2-HPCL
A 2-hydroxy carboxyl compound (instead of a 2-keto carboxyl compound) is a rather unusual substrate for thiamine dependent decarboxylases In all TPP-dependent reactions described so far, catalysis involves activation of the C2-H of the thiazole ring, followed by a nucleophilic attack at the carbonyl carbon of the substrate [49] By use of nuclear magnetic resonance spectroscopy, it has been shown that in the enzyme-bound state, the C2 proton of TPP is undissociated, but that the protein component dramatically accelerates the deprotonation, producing an intermediate C2 carbanion with a short lifetime [50,51] Most likely, the formation of a carbanion is also required for the cleavage of 2-hydroxy-3-methylacyl-CoAs by 2-HPCL (Fig 5) How-ever, this carbanion will attack carbon 1 of the substrate, which is highly reactive due to the nature of the thioester bond Ultimately this leads to the formation of formyl-CoA and a 2-methyl-branched fatty aldehyde
Fig 4 Alignment of the cofactor-binding consensus domain in TPP-dependent enzymes An alignment [26] is given of the cofactor-binding consensus domain in several TPP-dependent enzymes (Sc PDC: S cerevisiae pyruvate decarboxylase; Ec ALS: E coli acetolactate synthase; Of OCD:
O formigenes oxalyl-CoA decarboxylase) and in Hs 2-HPCL and its homologues in lower organisms (Ce OCD: C elegans putative oxalyl-CoA decarboxylase; Sc OCD: S cerevisiae putative oxalyl-CoA decarboxylase) The TPP-binding consensus motif, here represented with 10 residues upstream and downstream, is defined as G-D-G-x-(24–27)-N-N [46] About 10 residues downstream of the G-D-G sequence, a negatively charged amino acid is present (E or D), followed about 5 and 11 residues further by a generally conserved alanine and proline residue, respectively Immediately preceding the N-N sequence is a cluster of 6 or 7 largely hydrophobic side-chains.
Trang 6As 2-hydroxy-acyl-CoA esters seem to be unusual
substrates for TPP-dependent enzymes, Jones et al [52]
proposed another mechanism for a-oxidation from the
conversion of 2-hydroxyphytanoyl-CoA onwards This
would involve hydrolysis of the CoA-ester (peroxisomal
thioesterases have been described [53]) and a subsequent
oxidation generating 2-ketophytanic acid, which would
then be cleaved by 2-HPCL, the enzyme described by us
[26] This hypothesis would turn 2-HPCL into a not so
unusual TPP-dependent enzyme as its substrate would
then be a 2-keto-compound However, the activity of
the required thioesterases toward the proposed substrate
has never been demonstrated and the 2-hydroxyacid
oxidase, present in kidney, is only active on
L-2-hydroxyphytanic acid [54], whereas the activity of
2-HPCL vs 2-hydroxy-3-methylacyl-CoA has
unequivo-cally been proven Moreover, if, according to the
hypothesis of Jones et al [52], a thioesterase and a
2-hydroxyacid oxidase would be involved, no
formyl-CoA/formate would be produced This would be in
contrast with the solid findings of several authors
[11,18,19,28,33,55]
Mapping of the 2-HPCL gene The human 2-HPCL gene has been mapped to chromo-some 3p25 (Foulon V., Vermeesch J., Mannaerts G.P., Casteels M., Van Veldhoven P.P.; unpublished results) The complete Hs 2-HPCL gene spans 40.8 kb and contains
17 exons, with intron sizes ranging from 190 bp to 4700 bp All exon-intron boundaries are conform to the consensus rules [56], ending in an AG doublet and starting with a GT pair
Gene defects of 2-HPCL associated with ARD?
Although several diseases are known to be associated with 3p25, none of these appear to be linked to 2-HPCL Moreover, up till now no patients with a deficient 2-HPCL, which would probably result in a clinical picture similar to ARD, have been identified The mapping of the 2-HPCL gene is a first step towards the finding and diagnosis of such patients
Deficient breakdown of phytanic acid Elevated serum levels of phytanic acid are typical for patients with an isolated defective a-oxidation but can also
be seen in patients with peroxisome biogenesis disorders
In the latter patients the accumulation of phytanic acid is only one of the features present [4]
The most typical clinical picture of an isolated defect in phytanic acid breakdown is described as ARD [2,3] The gradual accumulation of phytanic acid in serum and tissues
of these patients results only in the second or third decade in distinct symptoms Virtually all patients show retinitis pigmentosa, night blindness and anosmia (deficient smelling sensation; 80% of ARD patients) In addition, polyneuro-pathy (60%), deafness (60%), ataxia (50%) and ichtyosis (20%) are quite common (for a review, see Wierzbicki et al [3]) A prerequisite for the diagnosis of ARD is the presence
of an elevated serum level of phytanic acid (above 200 lM
whereas normal phytanic acid levels in serum are below
30 lM) However, there seems to be no strict correlation between the level of phytanic acid accumulation and the severity of the clinical symptoms Interestingly, 30–40%
of the patients are born with an absence of one of the metacarpals or metatarsals (bone in the hand or forefoot, respectively)
The pathophysiology and the cause of the retinal and specific neurological manifestations of ARD remain at present unknown Feeding control animals excessive amounts of phytol can lead to similar severe neurological symptoms as in ARD, indicating that at least some of the symptoms in ARD might be directly related to an accumu-lation of phytanic acid Most obviously, the study of animal models for ARD will help to clarify the pathogenetic mechanisms of this disease
The clinical spectrum of ARD can be ascribed to different molecular and genetic defects [57] Probably most frequent
is a defect at the level of PAHX, mapped to chromosome 10p15.1 [22,23] However, some patients show a low or absent phytanoyl-CoA hydroxylase activity, but no muta-tion in PAHX Van den Brink et al [58] described in 2 such
Fig 5 Generation of a carbanion in enzyme-bound TPP and proposed
reaction mechanism for 2-HPCL In order to react with the substrate,
the C2-H of TPP must be activated by the protein component A key
function for this activation is the interaction of a conserved glutamate
[50,51] with the N1¢ atom of the coenzyme, resulting in an increased
basicity of its 4¢ amino group, facilitating the deprotonation of the C2.
Trang 7patients, who had been clinically diagnosed as ARD, a
mutation in the gene encoding PEX7p, the PTS2 import
receptor, apparently resulting in a deficient peroxisomal
import of the PTS2 containing PAHX These patients had
normal peroxisomes, normal peroxisomal b-oxidation, no
or very low PAHX activity, and deficient plasmalogen
synthesis, which is also dependent on an intact import of
PTS2 containing proteins So far, PEX7 mutations were
known to cause rhizomelic chondrodysplasia punctata
(RCDP), resulting in a short lifespan [59–61], but they can
apparently also result in a much milder phenotype with late
onset Additionally, Ferdinandusse et al described two
atypical ÔARDÕ patients, who eventually appeared to have a
racemase deficiency [62] (see legend to Fig 3) Nevertheless,
in some patients with the clinical syndrome of ARD none of
these specific molecular defects could be found and the
genetic basis of the disease in these patients awaits to be
defined
Conclusions and perspectives
2-HPCL is the first mammalian peroxisomal enzyme that is
TPP dependent This finding raises several questions
discussed below
(a) The TPP dependence of 2-HPCL renders the
a-oxidation pathway thiamine dependent as a whole This
could imply that the thiamine status of the cell would
influence the a-oxidation process, but so far no indication
pointing to this hypothesis can be found in the literature
Preliminary experiments with cultured C6-glia cells or
control human fibroblasts in thiamine-deficient conditions
(generated either by the addition of oxythiamine to the
growth medium, or by culturing cells in thiamine-depleted
medium) showed a decrease of the overall fluxthrough
the a-oxidation pathway (V Foulon, M Casteels &
P.P Van Veldhoven, unpublished results) Whether
overall a-oxidation would be deficient in patients with
thiamine deficiency as, e.g thiamine responsive
megalo-blastic anemia (TRMA), and whether this would lead to an
accumulation of phytanic acid in these patients, remains to
be investigated
(b) A TPP dependent reaction in peroxisomes requires
the presence of thiamine or thiamine pyrophosphate
inside the peroxisome It was shown recently that the
thiamine transporter SLC19A2, which is deficient in
TRMA, is not only present on the plasma membrane
but also on the mitochondrial membrane [63] No report
was made however, on the presence of this transporter
(or one of his homologues) on the peroxisomal
mem-brane As 2-HPCL is the first mammalian peroxisomal
enzyme described to be TPP-dependent, the mechanism
for the import of thiamine/TPP into peroxisomes remains
to be explored
Acknowledgements
This work was supported by grants from the ÔGeconcerteerde
onderzoeksacties van de Vlaamse GemeenschapÕ (GOA 94/98–12 and
GOA 99/03–09) and from the ÔFonds voor Wetenschappelijk
Onder-zoek-VlaanderenÕ (G-0239.98, G.0164.96 N and G.0115.02) V.F was
supported by a fellowship from the ÔFonds voor Wetenschappelijk
Onderzoek-VlaanderenÕ.
References
1 Klenk, E & Kahlke, W (1963) U¨ber das Vorkommen der 3,7,11,15-Tetramethylhexadecansa¨ure (Phytansa¨ure) in den Cho-lesterinestern und andere Lipidfractionen der Organe bei einem Krankheitsfall unbekannter Genese (Verdacht auf Heredopathia Atactica Polyneuritiformis [Refsum Syndrome]) Hoppe Zeilers Z Physiol Chem 333, 133–139.
2 Steinberg, D (1995) Refsum disease In The Metabolic and Molecular Bases of Inherited Disease (C.R Scriver, A.L Beaudet, W.S Sly & D Valle, eds.), 7th edn, pp 2351–2369 McGraw-Hill, New York.
3 Wierzbicki, A.S., Lloyd, M.D., Schofield, C.J., Feher, M.D & Gibberd, F.B (2002) Refsum’s disease: a peroxisomal disorder affecting phytanic acid a-oxidation J Neurochem 80, 727–735.
4 Brosius, U & Ga¨rtner, J (2002) Cellular and molecular aspects of Zellweger syndrome and other peroxisome biogenesis disorders Cell Mol Life Sci 59, 1058–1069.
5 Brenton, D.P & Krywawych, S (1982) 3-Methyladipate excretion
in Refsum’s disease Lancet 1, 624.
6 Try, K (1968) The in vitro omega-oxidation of phytanic acid and other branched chain fatty acids by mammalian liver Scand.
J Laboratory Invest 22, 224–230.
7 Wierzbicki, A.S., Mayne, P.D., Lloyd, M.D., Burston, D., Mei, G., Sidey, M.C., Feher, M.D & Gibberd, F.B (2002) Metabolism of phytanic acid and 3-methyl-adipic acids in patients with Adult Refsum’s disease In Peroxisomal Disorders and Regulation of Genes, 25–28 September 2002, Belgian Society for Cell and Developmental Biology, Ghent, Belgium.
8 Mannaerts, G.P., Van Veldhoven, P.P & Casteels, M (2000) Peroxisomal lipid degradation via a- and b-oxidation in mammals Cell Biochem Biophysics 32, 73–87.
9 Terlecky, S.R & Fransen, M (2000) How peroxisomes arise Traffic 1, 465–473.
10 Van Veldhoven, P.P., Huang, S., Eyssen, H.J & Mannaerts, G.P (1993) The deficient degradation of synthetic 2- and 3-methyl-branched fatty acids in fibroblasts from patients with peroxisomal disorders J Inher Metab Dis 16, 381–391.
11 Poulos, A., Sharp, P., Singh, H., Johnson, D.W., Carey, W.F & Easton, C (1993) Formic acid is a product of the a-oxidation of fatty acids by human skin fibroblasts: deficiency of formic acid production in peroxisome-deficient fibroblasts Biochem J 292, 457–461.
12 Watkins, P.A., Howard, A.E., Gould, S.J., Avigan, J & Mihalik, S.J (1996) Phytanic acid activation in rat liver peroxisomes is catalyzed by long-chain acyl-CoA synthetase J Lipid Res 37, 2288–2295.
13 Pahan, K., Cofer, K., Baliga, P & Singh, I (1993) Identification
of phytanoyl-CoA ligase as a distinct acyl-CoA ligase in peroxi-somes from cultured human skin fibroblasts FEBS Lett 322, 101– 104.
14 Steinberg, S.J., Wang, S.J., Kim, D.G., Mihalik, S.J & Watkins, P.A (1999) Human very-long-chain acyl-CoA synthetase: cloning, topography, and relevance to branched-chain fatty acid metabo-lism Biochem Biophys Res Commun 257, 615–621.
15 Croes, K., Casteels, M., Van Veldhoven, P.P & Mannaerts, G.P (1995) Evidence for the importance of iron in the alpha-oxidation
of 3-methyl-substituted fatty acids in the intact cell Biochimica Biophysica Acta 1255, 63–67.
16 Tsai, S.C., Avigan, J & Steinberg, D (1969) Studies on the alpha-oxidation of phytanic acid by rat liver mitochondria J Biol Chem 244, 2682–2692.
17 Huang, S., Van Veldhoven, P.P., Vanhoutte, F., Parmentier, G., Eyssen, H.J & Mannaerts, G.P (1992) a-Oxidation of 3-methyl-substituted fatty acids in rat liver Arch Biochem Biophys 296, 214–223.
Trang 818 Mihalik, S.J., Rainville, A.M & Watkins, P.A (1995) Phytanic
acid a-oxidaton in rat liver peroxisomes Production of
a-hydroxyphytanoyl-CoA and formate is enhanced by
dioxyge-nase cofactors Eur J Biochem 232, 545–551.
19 Croes, K., Casteels, M., Mannaerts, G.P & Van Veldhoven, P.P.
(1996) a-Oxidation of 3-methyl-substituted fatty acids in rat liver.
Production of formic acid instead of CO 2 , cofactor requirements,
subcellular localization and formation of a
2-hydroxy-3-methyl-acyl-CoA intermediate Eur J Biochem 240, 674–683.
20 Jansen, G.A., Mihalik, S.J., Watkins, P.A., Moser, H.W., Jakobs,
C., Denis, S & Wanders, R.J.A (1996) Phytanoyl-CoA
hydro-xylase is present in human liver, located in peroxisomes, and
deficient in Zellweger syndrome: direct, unequivocal evidence for
the new, revised pathway of phytanic acid a-oxidation in humans.
Biochem Biophys Res Commun 229, 205–210.
21 Croes, K., Foulon, V., Casteels, M., Van Veldhoven, P.P &
Mannaerts, G.P (2000) Phytanoyl-CoA hydroxylase: recognition
of 3-methyl-branched acyl-CoAs and requirement for GTP or
ATP and Mg2+in addition to its known hydroxylation cofactors.
J Lipid Res 41, 629–636.
22 Mihalik, S.J., Morrell, J.C., Kim, D., Sacksteder, K.A., Watkins,
P.A & Gould, S.J (1997) Identification of PAHX, a Refsum
disease gene Nat Genet 17, 185–189.
23 Jansen, G.A., Ofman, R., Ferdinandusse, S., Ijlst, L., Muijsers,
A.O., Skjeldal, O.H., Stokke, O., Jakobs, C., Besley, G.T.N.,
Wraith, J.E & Wanders, R.J.A (1997) Refsum disease is caused
by mutations in the phytanoyl-CoA hydroxylase gene Nat Genet.
17, 190–193.
24 Jansen, G.A., Hogenhout, E.M., Ferdinandusse, S., Waterham,
H.R., Ofman, R., Jakobs, C., Skjeldal, O.H & Wanders, R.J.
(2000) Human phytanoyl-CoA hydroxylase: resolution of the gene
structure and the molecular basis of Refsum’s disease Hum Mol.
Genet 9, 1195–1200.
25 Mukherji, M., Chien, W., Kershaw, N.J., Clifton, I.J., Schofield,
C.J., Wierzbicki, A.S & Lloyd, M.D (2001) Structure-function
analysis of phytanoyl-CoA 2-hydroxylase mutations causing
Refsum’s disease Hum Mol Genet 10, 1971–1982.
26 Foulon, V., Antonenkov, V.D., Croes, K., Waelkens, E.,
Mannaerts, G.P., Van Veldhoven, P.P & Casteels, M (1999)
Purification, molecular cloning, and expression of
2-hydroxy-phytanoyl-CoA lyase, a peroxisomal thiamine
pyrophosphate-dependent enzyme that catalyzes the carbon-carbon bond cleavage
during alpha-oxidation of 3-methyl-branched fatty acids Proc.
Natl Acad Sci USA 96, 10039–10044.
27 Jansen, G.A., Denis, S., Verhoeven, N.M., Jakobs, C & Wanders,
R.J (2000) Phytanic acid alpha-oxidation in man: identification of
2-hydroxyphytanoyl-CoA lyase, a peroxisomal enzyme with normal
activity in Zellweger syndrome J Inherit Metab Dis 23, 421–424.
28 Croes, K., Van Veldhoven, P.P., Mannaerts, G.P & Casteels, M.
(1997) Production of formyl-CoA during peroxisomal a-oxidation
of 3-methyl-branched fatty acids FEBS Lett 407, 197–200.
29 Croes, K., Casteels, M., Asselberghs, S., Herdewijn, P.,
Manna-erts, G.P & Van Veldhoven, P.P (1997) Formation of a
2-methyl-branched fatty aldehyde during peroxisomal a-oxidation FEBS
Lett 412, 643–645.
30 Verhoeven, N.M., Schor, D.S.M., ten Brink, H.J., Wanders,
R.J.A & Jakobs, C (1997) Resolution of the phytanic acid
a-oxidation pathway: identification of pristanal as product of the
decarboxylation of 2-hydroxyphytanoyl-CoA Biochem Biophys.
Res Commun 237, 33–36.
31 Verhoeven, N.M., Jakobs, C., Carney, G., Somers, M.P.,
Wan-ders, R.J & Rizzo, W.B (1998) Involvement of microsomal fatty
aldehyde dehydrogenase in the alpha-oxidation of phytanic acid.
FEBS Lett 429, 225–228.
32 Jansen, G.A., van den Brink, D.M., Ofman, R., Draghici, O.,
Dacremont, G & Wanders, R.J (2001) Identification of pristanal
dehydrogenase activity in peroxisomes: conclusive evidence that the complete phytanic acid alpha-oxidation pathway is localized in peroxisomes Biochem Biophys Res Commun 283, 674–679.
33 Casteels, M., Croes, K., Van Veldhoven, P.P & Mannaerts, G.P (1994) Aminotriazole is a potent inhibitor of a-oxidation of, 3-methyl-substituted fatty acids in rat liver Biochem Pharmacol.
48, 1973–1975.
34 Palese, M & Tephly, T.R (1975) Metabolism of formate in the rat J Toxicol Environ Health 1, 13–24.
35 Igamberdiev, A.U & Lea, P.J (2002) The role of peroxisomes in the integration of metabolism and evolutionary diversity of pho-tosynthetic organisms Phytochemistry 60, 651–674.
36 Mukherji, M., Kershaw, N.J., Schofield, C.J., Wierzbicki, A.S & Lloyd, M.D (2002) Utilization of sterol carrier protein-2 by phytanoyl-CoA hydroxylase in the peroxisomal a-oxidation of phytanic acid Chem Biol 9, 597–605.
37 Tsai, S.C., Steinberg, D., Avigan, J & Fales, H.M (1973) Studies
on the stereospecificity of mitochondrial oxidation of phytanic acid and of a-hydroxyphytanic acid J Biol Chem 246, 1091– 1097.
38 Croes, K., Casteels, M., Dieuaide-Noubhani, M., Mannaerts, G.P & Van Veldhoven, P.P (1999) Stereochemistry of the a-oxidation of 3-methyl-branched fatty acids in rat liver J Lipid Res 40, 601–609.
39 Foulon, V (2001) a-Oxidation of 3-Methyl-Branched Fatty Acids: Study of the Enzymes Involved in the Reaction Sequence PhD Thesis Leuven University Press, Leuven.
40 Schmitz, W & Conzelmann, E (1997) Stereochemistry of peroxi-somal and mitochondrial b-oxidation of a-methyacyl-CoAs Eur.
J Biochem 244, 434–440.
41 Burrell, J.W.K., Jackman, L.M & Weedon, B.C.L (1959) Stereochemistry and synthesis of phytol, geraniol, and nerol Proceedings of the Chem Soc 263–264.
42 Ackman, R.G & Hansen, R.P (1967) The occurrence of dia-stereoisomers of phytanic and pristanic acids and their determi-nation by gas-liquid chromatography Lipids 2, 357–362.
43 Antonenkov, V.D., Pirozhkov, S.J & Panchenko, L.F (1985) Intraparticulate localization and some properties of a clofibrate-induced peroxisomal aldehyde dehydrogenase from rat liver Eur.
J Biochem 149, 159–167.
44 Baetz, A.L & Allison, M.J (1989) Purification and characteriza-tion of oxalyl-coenzyme A decarboxylase from Oxalobacter for-migenes J Bacteriol 171, 2605–2608.
45 Lung, H.Y., Baetz, A.L & Peck, A.B (1994) Molecular cloning, DNA sequence, and gene expression of the oxalyl-coenzyme A decarboxylase gene, oxc, from the bacterium Oxalobacter for-migenes J Bacteriol 176, 2468–2472.
46 Hawkins, C.F., Borges, A & Perham, R.N (1989) A common structural motif in thiamin pyrophosphate-binding enzymes FEBS Lett 255, 77–82.
47 Lametschwandtner, G., Brocard, C., Fransen, M., Van Veldhoven, P.P., Berger, J & Hartig, A (1998) The difference in recognition
of terminal tripeptides as peroxisomal targeting signal 1 between yeast and human is due to different affinities of their receptor Pex5p to the cognate signal and to residues adjacent to it J Biol Chem 273, 33635–33643.
48 Baes, M., Gressens, P., Baumgart, E., Carmeliet, P., Casteels, M., Fransen, M., Evrard, P., Fahimi, D., Declercq, P.E., Collen, D., Van Veldhoven, P.P & Mannaerts, G.P (1997) A mouse model for Zellweger syndrome Nat Genet 17, 49–56.
49 Tittmann, K., Mesch, K., Pohl, M & Hu¨bner, G (1998) Acti-vation of thiamine diphosphate carboxylase from Zymomonas mobilis FEBS Lett 441, 404–406.
50 Kern, D., Kern, G., Neef, H., Tittmann, K., Killenberg-Jabs, M., Wikner, C., Schneider, G & Hu¨bner, G (1997) How thiamine diphosphate is activated in enzymes Science 275, 67–70.
Trang 951 Wikner, C., Meshalkina, L., Nilsson, U., Nikkola, M., Lindqvist,
Y., Sunstro¨m, M & Schneider, G (1994) Analysis of an invariant
cofactor–protein interaction in thiamin diphosphate-dependent
enzymes by site-directed mutagenesis J Biol Chem 269, 32144–
32150.
52 Jones, J.M., Morell, J.C & Gould, S.J (2000) Identification and
characterization of HAOX1, HAOX2, and HAOX3, three human
peroxisomal 2-hydroxy acid oxidases J Biol Chem 275, 12590–
12597.
53 Jones, J.M., Nau, K., Geraghty, M.T., Erdmann, R & Gould, S.J.
(1999) Identification of peroxisomal acyl-CoA thioesterases in
yeast and humans J Biol Chem 274, 9216–9223.
54 Draye, J.P., Van Hoof, F., de Hoffmann, E & Vamecq, J (1987)
Peroxisomal oxidation of L-2-hydroxyphytanic acid in rat kidney
cortex Eur J Biochem 167, 573–578.
55 Verhoeven, N.M., Schor, D.S.M., Previs, S.F., Brunengraber, H.
& Jakobs, C (1997) Stable isotope studies of phytanic acid
a-oxidation: in vivo production of formic acid Eur J Pediatr 156,
S83–S87.
56 Mount, S.M (1982) A catalogue of splice junction sequences.
Nucleic Acid Res 10, 459–472.
57 Wierzbicki, A.S., Mitchell, J., Lambert-Hammill, M., Hancock,
M., Greenwood, J., Sidey, M.C., de Belleroche, J & Gibberd, F.B.
(2000) Identification of genetic heterogeneity in Refsum’s disease.
Eur J Hum Genet 8, 649–651.
58 Van den Brink, D.M., Brites, P., Haasjes, J., Wierzbicki, A.S.,
Mitchell, J., Lambert-Hamill, M., de Belleroche, J., Jansen, G.A.,
Waterham, H.R & Wanders (2003) Identification of PEX7 as the second gene involved in Refsum disease Am J Hum Genet 72, 471–477.
59 Braverman, N., Steel, G., Obie, C., Moser, A., Moser, H., Gould, S.J & Valle, D (1997) Human PEX7 encodes the peroxisomal PTS2 receptor and is responsible for rhizomelic chondrodysplasia punctata Nat Genet 15, 369–376.
60 Motley, A.M., Hettema, E.H., Hogenhout, E.M., Brites, P., ten Asbroek, A.L.M.A., Wijburg, F.A., Baas, F., Heijmans, H.S., Tabak, H.F., Wanders, R.J.A & Distel, B (1997) Rhizomelic chondrodysplasia punctata is a peroxisomal protein targeting disease caused by a non-functional PTS2 receptor Nat Genet 15, 377–380.
61 Purdue, P.E., Zhang, J.W., Skoneczny, M & Lazarow, P (1997) Rhizomelic chondrodysplasia punctata is caused by deficiency of human PEX7, a homologue of the yeast PTS2 receptor Nat Genet 15, 381–384.
62 Ferdinandusse, S., Denis, S., Clayton, P.T., Graham, A., Rees, J.E., Allen, J.T., McLean, B.N., Brown, A.Y.P., Vreken, H.R., Waterham, R.J.A & Wanders (2000) Mutations in the gene encoding peroxisomal alpha-methylacyl-CoA racemase cause adult-onset sensory motor neuropathy Nat Genet 24, 188– 191.
63 Song, Q & Singleton, C.K (2002) Mitochondria from cultured cells derived from normal and thiamine-responsive megaloblastic anemia individuals efficiently import thiamine diphosphate BMC Biochem 3, 8.